Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Slides:

Advertisements

Similar presentations

Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with.

Advertisements

Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation Yuan.

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

B Cells in Chronic Graft-versus-Host Disease

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation Marta Palomo,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation Imad Abboud, Raphaël Porcher,

Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease Nathan Cantoni, Hans H. Hirsch, Nina.

Joseph Pidala, Stephanie J

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft- Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease Hildegard T. Greinix, Zoya Kuzmina,

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

What is quality in a transplant program?

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Biology of Blood and Marrow Transplantation

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,

Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy William A.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Bone Marrow B cell Precursor Number after Allogeneic Stem Cell Transplantation and GVHD Development Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H. Dunphy, Andrew Sharf, Thomas C. Shea, Jonathan S. Serody, Stefanie Sarantopoulos Biology of Blood and Marrow Transplantation Volume 18, Issue 6, Pages 968-973 (June 2012) DOI: 10.1016/j.bbmt.2012.03.005 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Morphologic and immunohistochemical analysis of day-30 post-hematopoietic stem cell transplantation (HSCT) bone marrow (BM) biopsies in patients who never developed or who developed chronic graft-versus-host disease (cGVHD). (A) Representative micrograph of terminal deoxynucleotidyl transferase (TdT) immunohistochemical staining in patients who never developed (“No cGVHD”) or who subsequently developed cGVHD (“Yes cGVHD”). (B) Absolute numbers of TdT+ BM B cell precursors in patients who never developed (−) vs those who later developed (+) cGVHD, in relation to steroid therapy at the time of BM evaluation (+ vs − steroid). Reference BM (“No HSCT”) showed significantly fewer precursors compared to the + or − cGHVD group after steroid effect was excluded (*P = .03 and P < .01, respectively). (C) Representative micrograph or PAX5 immunohistochemical staining in patients who never developed (“No cGVHD”) or who develop cGVHD (“Yes cGVHD”). (D) Total BM B cell number as determined by PAX5 staining in patients who never developed (−) vs those who developed (+) cGVHD, currently (+), or never treated with (−) steroids. Compared to the reference samples (“No HSCT”), total B cell numbers were similar between patients who had undergone HSCT; NS indicating not significant. (E) Representative micrograph of CD3 immunohistochemical staining in patients who never developed (“No cGVHD”) or who develop cGVHD (“Yes cGVHD”). (F) Absolute CD3+ T cell number in patients who never developed (−) or developed (+) cGVHD, either treated with (+) steroids or never treated with (−) steroids. Reference BM (“No HSCT”) showed significantly more CD3+ T cells compared to the + or − cGVHD group after steroid therapy was excluded (*P = .04 and P < .01, respectively). Description of patient groups: −cGVHD (total n = 15): patients who never developed cGVHD including those who received steroid treatment for acute GVHD (aGVHD; n = 3) and patients who were not receiving steroid treatment at the time of BM biopsy (n = 12), followed for a total median of 792 and 980 days, respectively. +cGVHD (total n = 15): patients who developed GVHD (n = 15) receiving high-dose steroids (≥0.5 mg/kg; n = 9) vs those without steroid therapy from time of HSCT to time of BM biopsy (n = 6), followed for a total median of 630 and 1100 days, respectively. No HSCT (total n=11): Age and gender-matched reference biopsies from untreated patients with non-Hodgkin lymphoma (NHL; diffuse large B cell lymphoma [n = 7]; low-grade NHL [n = 2], follicular lymphoma, grade 3 [n = 1], classic Hodgkin lymphoma [n = 1]) who underwent staging BM evaluation. For all micrographs, the original magnification was 600×. Box and whisker plots express the median, 25th and 75th percentile at the ends of the box, and 5th and 95th percentile at the ends of the whiskers. Biology of Blood and Marrow Transplantation 2012 18, 968-973DOI: (10.1016/j.bbmt.2012.03.005) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions